Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

Phase 1

Completed

Conditions: Autoimmune Disorder
Healthy Volunteers

Interventions: Drug: Rilzabrutinib amorphous form
Drug: Rilzabrutinib crystalline form

First Posted Date: 2024-04-02

Last Posted Date: 2024-04-30

Lead Sponsor: Sanofi

Target Recruit Count: 28

Registration Number: NCT06342700

Locations: 🇺🇸
Nucleus Network Site Number : 8400001, Saint Paul, Minnesota, United States

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

Phase 1

Completed

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: Humanized anti-Factor Bb monoclonal antibody
Drug: Placebo

First Posted Date: 2024-03-22

Last Posted Date: 2024-03-22

Lead Sponsor: Sanofi

Target Recruit Count: 54

Registration Number: NCT06326814

Locations: 🇺🇸
Parexel International Site Number : 8400002, Glendale, California, United States
🇺🇸
Parexel International Site Number : 8400003, Baltimore, Maryland, United States

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

Phase 3

Recruiting

Conditions: Prurigo Nodularis

Interventions: Drug: Dupilumab

First Posted Date: 2024-03-05

Last Posted Date: 2025-03-07

Lead Sponsor: Sanofi

Target Recruit Count: 18

Registration Number: NCT06293053

Locations: 🇺🇸
Mission Dermatology Center- Site Number : 8400011, Rancho Santa Margarita, California, United States
🇺🇸
Pediatric Center of Excellence (PCE) - Miami Pediatric Endocrinology- Site Number : 8400005, Coral Gables, Florida, United States
🇺🇸
Life Clinical Trials- Site Number : 8400018, Coral Springs, Florida, United States

and more 8 locations

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Phase 3

Recruiting

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy

Interventions: Drug: riliprubart
Drug: Placebo
Drug: IVIg

First Posted Date: 2024-03-04

Last Posted Date: 2025-05-23

Lead Sponsor: Sanofi

Target Recruit Count: 160

Registration Number: NCT06290141

Locations: 🇨🇳
Investigational Site Number : 1560006, Wuhan, China
🇨🇳
Investigational Site Number : 1560004, Xi'an, China
🇨🇿
Investigational Site Number : 2030004, Brno, Czechia

and more 79 locations

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

Phase 3

Recruiting

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Polyneuropathy, Inflammatory Demyelinating, Chronic

Interventions: Drug: Riliprubart
Drug: Placebo

First Posted Date: 2024-03-04

Last Posted Date: 2025-05-23

Lead Sponsor: Sanofi

Target Recruit Count: 140

Registration Number: NCT06290128

Locations: 🇩🇪
Investigational Site Number : 2760001, Bad Homburg, Germany
🇬🇷
Investigational Site Number : 3000002, Athens, Greece
🇫🇷
Investigational Site Number : 2500005, Montpellier, France

and more 93 locations

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

Phase 2

Active, not recruiting

Conditions: Bronchiectasis

Interventions: Drug: Itepekimab (SAR440340)
Drug: Placebo

First Posted Date: 2024-02-28

Last Posted Date: 2025-04-29

Lead Sponsor: Sanofi

Target Recruit Count: 300

Registration Number: NCT06280391

Locations: 🇮🇱
Investigational Site Number : 3760009, Ramat Gan, Israel
🇮🇱
Investigational Site Number : 3760004, Rehovot, Israel
🇮🇱
Investigational Site Number : 3760007, Tel Aviv, Israel

and more 135 locations

Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy

Active, not recruiting

Conditions: Pertussis (Whooping Cough)

Interventions: Other: Not applicable / database analysis

First Posted Date: 2024-02-14

Last Posted Date: 2024-04-19

Lead Sponsor: Sanofi

Target Recruit Count: 365000

Registration Number: NCT06258057

Locations: 🇫🇷
Investigational Site, Chilly-Mazarin, France

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Phase 3

Recruiting

Conditions: Dermatitis Atopic

Interventions: Drug: Amlitelimab
Drug: Placebo
Drug: Topical corticosteroids
Drug: Topical tacrolimus or pimecrolimus

First Posted Date: 2024-02-05

Last Posted Date: 2025-05-22

Lead Sponsor: Sanofi

Target Recruit Count: 249

Registration Number: NCT06241118

Locations: 🇺🇸
University of Alabama at Birmingham- Site Number : 8401267, Birmingham, Alabama, United States
🇺🇸
Center for Dermatology and Plastic Surgery- Site Number : 8401119, Scottsdale, Arizona, United States
🇺🇸
Arkansas Dermatology - North Little Rock- Site Number : 8401244, North Little Rock, Arkansas, United States

and more 138 locations

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Phase 3

Active, not recruiting

Conditions: Dermatitis Atopic

Interventions: Drug: Placebo
Drug: Amlitelimab
Drug: Topical corticosteroids
Drug: Topical calcineurin inhibitors

First Posted Date: 2024-01-25

Last Posted Date: 2025-05-02

Lead Sponsor: Sanofi

Target Recruit Count: 643

Registration Number: NCT06224348

Locations: 🇨🇳
Investigational Site Number : 1560047, Tianjin, China
🇨🇳
Investigational Site Number : 1560049, Wuhan, China
🇨🇳
Investigational Site Number : 1560003, Wuxi, China

and more 162 locations

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

Phase 3

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Itepekimab (SAR440340)
Drug: Placebo

First Posted Date: 2024-01-17

Last Posted Date: 2025-04-16

Lead Sponsor: Sanofi

Target Recruit Count: 700

Registration Number: NCT06208306

Locations: 🇬🇧
Investigational Site Number : 8260004, Portsmouth, Hampshire, United Kingdom
🇨🇳
Investigational Site Number : 1560019, Pingxiang, China
🇨🇳
Investigational Site Number : 1560020, Shanghai, China

and more 220 locations

Home Terms & Conditions Privacy Policy